Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$13.75
+0.2%
$11.36
$7.83
$21.00
$624.86M11.67 million shs3.51 million shs
Embecta Corp. stock logo
EMBC
Embecta
$9.87
-0.5%
$10.21
$9.20
$21.48
$579.75M1.08526,296 shs581,530 shs
Profound Medical stock logo
PROF
Profound Medical
$5.51
-1.3%
$5.92
$3.89
$10.25
$167.70M0.5233,492 shs9,611 shs
ZimVie Inc. stock logo
ZIMV
ZimVie
$18.82
-0.2%
$11.68
$8.15
$18.98
$531.87M2.21.21 million shs239,491 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
+0.22%+4.17%+21.04%+8.86%+75.61%
Embecta Corp. stock logo
EMBC
Embecta
-0.50%-5.55%-1.60%-25.79%-31.32%
Profound Medical stock logo
PROF
Profound Medical
-1.25%-0.72%-9.52%+10.89%-41.69%
ZimVie Inc. stock logo
ZIMV
ZimVie
-0.21%-0.32%+99.58%+104.79%+9.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AxoGen, Inc. stock logo
AXGN
AxoGen
2.3491 of 5 stars
3.51.00.00.02.32.50.6
Embecta Corp. stock logo
EMBC
Embecta
4.7439 of 5 stars
3.23.03.30.03.53.33.8
Profound Medical stock logo
PROF
Profound Medical
1.8453 of 5 stars
3.51.00.00.00.62.50.6
ZimVie Inc. stock logo
ZIMV
ZimVie
0.9321 of 5 stars
1.05.00.00.02.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
3.00
Buy$24.5078.18% Upside
Embecta Corp. stock logo
EMBC
Embecta
2.33
Hold$19.0092.50% Upside
Profound Medical stock logo
PROF
Profound Medical
3.00
Buy$11.0099.64% Upside
ZimVie Inc. stock logo
ZIMV
ZimVie
2.00
Hold$17.75-5.69% Downside

Current Analyst Ratings Breakdown

Latest PROF, EMBC, AXGN, and ZIMV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$19.00
7/22/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$9.00 ➝ $19.00
7/16/2025
Embecta Corp. stock logo
EMBC
Embecta
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$13.00 ➝ $12.00
5/23/2025
Embecta Corp. stock logo
EMBC
Embecta
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$25.00
5/23/2025
Embecta Corp. stock logo
EMBC
Embecta
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.00
5/15/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $10.00
5/13/2025
AxoGen, Inc. stock logo
AXGN
AxoGen
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$26.00 ➝ $24.00
5/9/2025
Profound Medical stock logo
PROF
Profound Medical
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Moderate Buy
(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$187.34M3.34N/AN/A$2.36 per share5.83
Embecta Corp. stock logo
EMBC
Embecta
$1.12B0.51$3.32 per share2.97($12.80) per share-0.77
Profound Medical stock logo
PROF
Profound Medical
$10.68M15.50N/AN/A$2.01 per share2.74
ZimVie Inc. stock logo
ZIMV
ZimVie
$449.75M1.18$1.85 per share10.15$14.64 per share1.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$9.96M-$0.10N/AN/AN/A-2.29%-4.53%-2.36%N/A
Embecta Corp. stock logo
EMBC
Embecta
$78.30M$0.9010.973.210.644.89%-19.67%12.27%8/8/2025 (Estimated)
Profound Medical stock logo
PROF
Profound Medical
-$27.82M-$1.22N/AN/AN/A-269.35%-70.41%-57.22%8/14/2025 (Estimated)
ZimVie Inc. stock logo
ZIMV
ZimVie
-$25.83M-$0.70N/AN/A-4.39%6.37%3.34%8/7/2025 (Estimated)

Latest PROF, EMBC, AXGN, and ZIMV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Profound Medical stock logo
PROF
Profound Medical
-$0.43N/AN/AN/A$4.75 millionN/A
8/8/2025Q3 2025
Embecta Corp. stock logo
EMBC
Embecta
$0.7720N/AN/AN/A$278.15 millionN/A
8/7/2025Q2 2025
ZimVie Inc. stock logo
ZIMV
ZimVie
$0.2285N/AN/AN/A$112.82 millionN/A
7/30/2025Q2 2025
ZimVie Inc. stock logo
ZIMV
ZimVie
$0.2080$0.26+$0.0520-$0.14$112.60 million$116.66 million
5/9/2025Q2 2025
Embecta Corp. stock logo
EMBC
Embecta
$0.66$0.70+$0.04$0.40$261.77 million$259.00 million
5/8/2025Q1 2025
Profound Medical stock logo
PROF
Profound Medical
-$0.29-$0.36-$0.07-$0.36$4.78 million$2.62 million
5/8/2025Q1 2025
ZimVie Inc. stock logo
ZIMV
ZimVie
$0.21$0.27+$0.06-$0.05$113.10 million$112.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
Embecta Corp. stock logo
EMBC
Embecta
$0.606.08%N/A66.67%N/A
Profound Medical stock logo
PROF
Profound Medical
N/AN/AN/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.63
4.28
2.65
Embecta Corp. stock logo
EMBC
Embecta
N/A
2.48
1.83
Profound Medical stock logo
PROF
Profound Medical
0.09
11.31
10.03
ZimVie Inc. stock logo
ZIMV
ZimVie
0.56
2.37
1.60

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
Embecta Corp. stock logo
EMBC
Embecta
93.83%
Profound Medical stock logo
PROF
Profound Medical
47.86%
ZimVie Inc. stock logo
ZIMV
ZimVie
95.63%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
2.78%
Embecta Corp. stock logo
EMBC
Embecta
0.42%
Profound Medical stock logo
PROF
Profound Medical
1.52%
ZimVie Inc. stock logo
ZIMV
ZimVie
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
45045.54 million44.28 millionOptionable
Embecta Corp. stock logo
EMBC
Embecta
2,10058.44 million58.20 millionOptionable
Profound Medical stock logo
PROF
Profound Medical
15030.05 million29.60 millionOptionable
ZimVie Inc. stock logo
ZIMV
ZimVie
1,77028.20 million27.35 millionOptionable

Recent News About These Companies

ZimVie (NASDAQ:ZIMV) Stock Rating Lowered by B. Riley
ZimVie Reports Second Quarter 2025 Financial Results
Insights into ZimVie's Upcoming Earnings
ZimVie to sell to investment firm for about $730M
BC-Most Active Stocks
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AxoGen stock logo

AxoGen NASDAQ:AXGN

$13.75 +0.03 (+0.22%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$14.23 +0.48 (+3.49%)
As of 08/6/2025 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Embecta stock logo

Embecta NASDAQ:EMBC

$9.87 -0.05 (-0.50%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$9.86 0.00 (-0.05%)
As of 08/6/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Profound Medical stock logo

Profound Medical NASDAQ:PROF

$5.51 -0.07 (-1.25%)
Closing price 08/6/2025 03:59 PM Eastern
Extended Trading
$5.44 -0.08 (-1.36%)
As of 08/6/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

ZimVie stock logo

ZimVie NASDAQ:ZIMV

$18.82 -0.04 (-0.21%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$18.82 0.00 (0.00%)
As of 08/6/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.